Literature DB >> 22963432

Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre.

A Adler1, M Gniadkowski, A Baraniak, R Izdebski, J Fiett, W Hryniewicz, S Malhotra-Kumar, H Goossens, C Lammens, Y Lerman, M Kazma, T Kotlovsky, Y Carmeli.   

Abstract

Increasing resistance due to the production of ESBL in Escherichia coli (ESBL-E. coli) has become a major threat to public health. Our aims were to study the incidence of ESBL-E. coli acquisition during hospitalization and the transmission rates of different ESBL-E. coli clones. This was a prospective case-control study, conducted in two geriatric rehabilitation wards in Tel-Aviv. Serial rectal cultures were collected from admission till discharge. All patient-unique ESBL-E. coli isolates were subjected to molecular typing by PFGE, MLST and determination of ESBL genes. An acquisition of ESBL-E. coli was defined as traceable when a patient with the same ST, PFGE type and ESBL gene was hospitalized in the same ward in parallel to the acquisition case. ESBL-E. colis were recovered from 125 patients out of 492 enrolled: 52 were recovered upon admission, 59 acquired ESBL-E. coli during their stay, and there was undetermined status in 14 patients. A low Norton's score was associated with acquisition (O.R. 1.14 for each point, 95% C.I. 1.01-1.29, p < 0.05). ESBL-E. coli infections (n = 9) had occurred only in ESBL-E. coli carriers. The pandemic ST131 clone was the most common (48/125). The majority of the isolates (101/125) produced CTX-M-type ESBL. Of the 59 acquisition cases, 32 were traced to another patient. In-hospital dissemination was highest in the CTX-M-27-producing ST131 and the SHV-5-producing ST372 sub-clones (acquisition/admission ratios of 17/11 and 9/3, respectively), with almost all cases traced to other patients. In conclusion, most ESBL-E. coli acquisition cases were traceable to other patients. The transmission potential varied significantly between ESBL-E. coli clones.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963432     DOI: 10.1111/j.1469-0691.2012.03999.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  23 in total

Review 1.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

3.  Independent Host Factors and Bacterial Genetic Determinants of the Emergence and Dominance of Escherichia coli Sequence Type 131 CTX-M-27 in a Community Pediatric Cohort Study.

Authors:  André Birgy; Corinne Levy; Marie-Hélène Nicolas-Chanoine; Aurélie Cointe; Claire A Hobson; Mélanie Magnan; Stéphane Bechet; Philippe Bidet; Robert Cohen; Stéphane Bonacorsi
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

4.  High rates of intestinal colonisation with fluoroquinolone-resistant ESBL-harbouring Enterobacteriaceae in hospitalised patients with antibiotic-associated diarrhoea.

Authors:  J Vervoort; M Gazin; M Kazma; T Kotlovsky; C Lammens; Y Carmeli; H Goossens; S Malhotra-Kumar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-04       Impact factor: 3.267

5.  Whole Genome Sequencing Detects Minimal Clustering Among Escherichia coli Sequence Type 131-H30 Isolates Collected From United States Children's Hospitals.

Authors:  Arianna Miles-Jay; Scott J Weissman; Amanda L Adler; Janet G Baseman; Danielle M Zerr
Journal:  J Pediatric Infect Dis Soc       Date:  2021-03-26       Impact factor: 3.164

6.  Clonal structure, extended-spectrum β-lactamases, and acquired AmpC-type cephalosporinases of Escherichia coli populations colonizing patients in rehabilitation centers in four countries.

Authors:  R Izdebski; A Baraniak; J Fiett; A Adler; M Kazma; J Salomon; C Lawrence; A Rossini; A Salvia; J Vidal Samso; J Fierro; M Paul; Y Lerman; S Malhotra-Kumar; C Lammens; H Goossens; W Hryniewicz; C Brun-Buisson; Y Carmeli; M Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

7.  Extensive Within-Host Diversity in Fecally Carried Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli Isolates: Implications for Transmission Analyses.

Authors:  N Stoesser; A E Sheppard; C E Moore; T Golubchik; C M Parry; P Nget; M Saroeun; N P J Day; A Giess; J R Johnson; T E A Peto; D W Crook; A S Walker
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

Review 8.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

Review 9.  Is patient isolation the single most important measure to prevent the spread of multidrug-resistant pathogens?

Authors:  Caroline Landelle; Leonardo Pagani; Stephan Harbarth
Journal:  Virulence       Date:  2013-01-09       Impact factor: 5.882

10.  Prospective Validation of Cessation of Contact Precautions for Extended-Spectrum β-Lactamase-Producing Escherichia coli(1).

Authors:  Sarah Tschudin-Sutter; Reno Frei; Friedbert Schwahn; Milanka Tomic; Martin Conzelmann; Anne Stranden; Andreas F Widmer
Journal:  Emerg Infect Dis       Date:  2016-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.